Primary adenosquamous carcinoma of the esophagus: an analysis of 39 cases

Ni, Peng-Zhi; Yang, Yu‐Shang; Hu, Weipeng; Wang, Wenping; Yuan, Yong; Chen, Long-Qi

doi:10.21037/jtd.2016.09.59

Cited by 21 publications

(32 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to JSED, the World Health Organization (WHO) distinguished ASC from MECE, in the 1990 WHO Classification of Tumors of the Esophagus. [ 3 ]…”

Section: Definition and Classificationmentioning

confidence: 99%

“…In patient series from both Asia[ 3 , 4 , 5 , 6 , 7 ] and the US,[ 8 , 9 ] the reported incidence rates range between 0.37%[5] and 1%. [ 3 , 7 , 9 ] The age and gender distribution is also consistent throughout the literature. ASC mostly presents in people older than 40 years, with incidence peaking around the 7th decade of life.…”

Section: Epidemiologymentioning

confidence: 99%

“…Literature on ASC is scare and mostly consists of small case series. [ 3 , 4 , 5 , 6 , 7 ] Only recently did larger case series emerge. [ 8 , 9 ] The purpose of this review is to summarize the existing data on epidemiology, pathogenesis, histopathology, clinical characteristics, diagnosis and staging of ASC, as well as treatment and prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adenosquamous carcinoma of the esophagus: A literature review

Schizas

Kapsampelis

Mylonas³

2018

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

Adenosquamous carcinoma (ASC) of the esophagus is an uncommon type of esophageal cancer that contains both adenocarcinoma and squamous cell carcinoma elements. Data on this biologically unique type of cancer are limited and mainly stem from case reports and small case series. We performed an audit of the available literature and synthesized a review on the epidemiology, pathogenesis, histopathology, clinical manifestations, diagnosis, treatment and prognosis of ASCs. Adenosquamous carcinoma of the esophagus is a rare type of esophageal cancer. Histological examination is necessary to confirm the diagnosis of ASC and patients usually receive multimodal treatment. Patient outcomes are not well defined and further research could help us better understand the pathophysiology and unique needs of patients with this rare malignancy.

show abstract

“…In addition to JSED, the World Health Organization (WHO) distinguished ASC from MECE, in the 1990 WHO Classification of Tumors of the Esophagus. [ 3 ]…”

Section: Definition and Classificationmentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adenosquamous carcinoma of the esophagus: A literature review

Schizas

Kapsampelis

Mylonas³

2018

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

show abstract

“…The number of EC cases diagnosed annually in China account for almost half of the worldwide total (2). Considering that early symptoms in EC are frequently latent, the majority of patients are diagnosed at the advanced stage and prognosis is usually poor, owing to invasion and metastasis (3)(4)(5). Therefore, it is urgent to identify novel and effective molecular targets for the diagnosis and treatment of EC for improved patient outcomes.…”

Section: Introductionmentioning

confidence: 99%

Cullin7 promotes epithelial‑mesenchymal transition of esophageal carcinoma via the ERK‑SNAI2 signaling pathway

et al. 2018

View full text Add to dashboard Cite

Cullin7 (CUL7) is a member of Cullin protein family and exhibits a tumor‑promoting role in several types of tumors, including breast, liver and ovarian. However, its roles in esophageal carcinoma (EC) have not yet been reported. In the present study, CUL7 expression in EC tissue was revealed to be significantly higher compared with nontumoral tissues, as detected by immunohistochemistry (IHC; P=0.000). χ2 analysis confirmed that CUL7 expression was positively associated with invasion depth (P=0.000), lymph node involvement (P=0.033) and advanced clinical stage (P=0.000). Survival analysis demonstrated that CUL7 was positively associated with poor overall survival (P=0.001) and poor disease‑free survival (P=0.0019). An association of CUL7 with endothelial‑mesenchymal transition (EMT) was examined, and IHC results indicated that high CUL7 expression was associated with increased zinc finger protein SNAI2 (SNAI2) expression (P=0.000) and decreased E‑cadherin (P=0.000). Western blot analysis demonstrated that short hairpin RNA silencing CUL7 in EC1 cells increased epithelial (E)‑cadherin protein expression level, and decreased expression of Vimentin and SNAI2; cell migration was also reduced. Western blot analysis demonstrated that over expression of CUL7 in EC9706 cells increased Vimentin and SNAI2 protein expression, but decreased E‑cadherin expression, and the number of migratory cells. Investigation into the potential molecular mechanisms demonstrated that over expressing CUL7 in EC9706 cells stimulated the phosphorylation of ERK. Inhibiting ERK through treatment with U0126 significantly abrogated CUL7‑induced alterations in Vimentin, SNAI2 and E‑cadherin expression levels. Results from the present study demonstrated that CUL7 expression was associated with EC progression and poor prognosis. CUL7 may promote EMT via the ERK‑SNAI2 pathway in EC. These data may improve our understanding of the role of CUL7 in tumors and provide supporting evidence for the development of novel therapeutic targets for EC.

show abstract

“…However, focal adenocarcinomatous differentiation occurs in ~20% of cases of esophageal invasive SCC (1,6). When the adenocarcinomatous features occupy considerable amounts of the esophageal SCC, tumors are classified as either adenosquamous carcinoma or mucoepidermoid carcinoma (1,2,(7)(8)(9)(10)(11). Adenocarcinomatous differentiation in SCC should be distinguished from acantholytic SCC (also called pseudoglandular or adenoid SCC) (12)(13)(14)(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Esophageal adenosquamous carcinoma mimicking acantholytic squamous cell carcinoma

et al. 2017

View full text Add to dashboard Cite

Herein is described a unique case of esophageal cancer mimicking acantholytic squamous cell carcinoma (SCC). The patient succumbed to the disease within one month of diagnosis. Autopsy revealed a 10-cm esophageal tumor, characterized by prominent acantholysis-like areas composed of discohesive cancer cells, along with nested growth of SCC. These discohesive cancer cells focally exhibited pagetoid extension into adjacent esophageal epithelium, comprised ~60% of the esophageal tumor volume and had widely metastasized to the lungs, chest wall, liver, spleen, right adrenal gland, bones and lymph nodes. No metastases of SCC were observed. SCC cells were immunohistochemically positive for keratin 5/6 and E-cadherin and were negative for mucin and carcinoembryonic antigen (CEA). However, the discohesive cancer cells exhibited negativity for keratin 5/6, positivity for mucin and CEA, and diminished or no immunostaining for E-cadherin. Thus, these discohesive cells represented true adenocarcinomatous differentiation rather than acantholytic SCC cells. It was concluded that this tumor was an esophageal adenosquamous carcinoma with 'pseudo'-acantholytic adenocarcinoma components, which should be considered as a rare but distinctive type of aggressive cancer.

show abstract

Primary adenosquamous carcinoma of the esophagus: an analysis of 39 cases

Cited by 21 publications

References 18 publications

Adenosquamous carcinoma of the esophagus: A literature review

Adenosquamous carcinoma of the esophagus: A literature review

Cullin7 promotes epithelial‑mesenchymal transition of esophageal carcinoma via the ERK‑SNAI2 signaling pathway

Esophageal adenosquamous carcinoma mimicking acantholytic squamous cell carcinoma

Contact Info

Product

Resources

About